- Home
- HRMY vs CRGY Comparison
HRMY vs CRGY Comparison
Compare HRMY & CRGY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HRMY | CRGY |
|---|---|---|
| Founded | 2017 | 1986 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Oil & Gas Production |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 3.3B |
| IPO Year | 2020 | 2022 |
Fundamental Metrics
Financial Performance| Metric | HRMY | CRGY |
|---|---|---|
| Price | $27.45 | $13.35 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 13 |
| Target Price | ★ $46.70 | $14.00 |
| AVG Volume (30 Days) | 604.0K | ★ 9.4M |
| Earning Date | 05-05-2026 | 05-04-2026 |
| Dividend Yield | N/A | ★ 3.77% |
| EPS Growth | ★ 7.97 | N/A |
| EPS | ★ 2.71 | N/A |
| Revenue | $868,453,000.00 | ★ $3,579,782,000.00 |
| Revenue This Year | $19.75 | $27.35 |
| Revenue Next Year | $12.88 | N/A |
| P/E Ratio | ★ $10.32 | $99.08 |
| Revenue Growth | 21.51 | ★ 22.14 |
| 52 Week Low | $25.52 | $6.83 |
| 52 Week High | $40.87 | $14.02 |
Technical Indicators
Market Signals| Indicator | HRMY | CRGY |
|---|---|---|
| Relative Strength Index (RSI) | 40.58 | 62.95 |
| Support Level | $25.71 | $8.29 |
| Resistance Level | $28.99 | N/A |
| Average True Range (ATR) | 0.76 | 0.55 |
| MACD | 0.28 | -0.02 |
| Stochastic Oscillator | 45.54 | 71.70 |
Price Performance
Historical ComparisonAbout HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
About CRGY Crescent Energy Company
Crescent Energy Co is an energy company committed to delivering value for shareholders through disciplined growth, acquisition ideas, and the consistent return of capital. Its long-life, balanced portfolio combines stable cash flows from low-decline production with deep, high-quality development inventory. The Company's investing and operating activities are focused in Texas and the Rocky Mountain region.